Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
Business Wire•04/11/2026•09:15 ET
0
Key Highlights
- ➤Gilead and Kite will present 23 ASH 2026 abstracts, including seven oral presentations
- ➤Anito-cel iMMagine-1 provides at least 18 months’ follow-up in relapsed/refractory multiple myeloma
- ➤FDA reviews anito-cel BLA with a December 23, 2026 PDUFA target date
- ➤Yescarta ZUMA-12 delivers five-year follow-up in first-line high-risk large B-cell lymphoma
- ➤Gamgertamig Phase 1b studies report initial results in relapsed/refractory autoimmune cytopenias
Expert Statements
Gallia Levy, Senior Vice President, Global Head of Development at Kite
“People living with blood cancers deserve treatments that offer more than a response; they deserve the possibility of lasting freedom from disease”
Gallia Levy, Senior Vice President, Global Head of Development at Kite
“The data we are presenting reflect the breadth of our leadership and our commitment to advancing next-generation cell therapy, so more patients can benefit across multiple cancers and throughout their treatment journey.”
Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
– iMMagine-1 Data Provide 18 Months Minimum Follow-Up on Anito-cel’s Durability and Safety in Relapsed or Refractory Multiple Myeloma –
Get started
Create a free account to read the full story.